Prediction of the differences in tumor mutation burden between primary and metastatic lesions by radiogenomics
Open Access
- 24 October 2021
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 113 (1) , 229-239
Abstract
Tumor mutational burden (TMB) is gaining attention as a biomarker for responses to immune checkpoint inhibitors in cancer patients. In this study, we evaluated the status of TMB in primary and liver metastatic lesions in patients with colorectal cancer (CRC). In addition, the status of TMB in primary and liver metastatic lesions was inferred by radiogenomics on the basis of computed tomography (CT) images. The study population included twenty-four CRC patients with liver metastases. DNA was extracted from primary and liver metastatic lesions obtained from the patients and TMB values were evaluated by next-generation sequencing. The TMB value was considered high when it equaled to or exceeded 10/100 Mb. Radiogenomic analysis of TMB was performed by machine learning using CT images and the construction of prediction models. In 7 out of 24 patients (29.2%), the TMB status differed between the primary and liver metastatic lesions. Radiogenomic analysis was performed to predict whether TMB status was high or low. The maximum values for the area under the receiver operating characteristic curve were 0.732 and 0.812 for primary CRC and CRC with liver metastasis, respectively. The sensitivity, specificity, and accuracy of the constructed models for TMB status discordance were 0.857, 0.600, and 0.682, respectively. Our results suggested that accurate inference of the TMB status is possible using radiogenomics. Thus, radiogenomics could facilitate the diagnosis, treatment, and prognosis of patients with CRC in the clinical setting.Keywords
This publication has 36 references indexed in Scilit:
- CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomesAbdominal Radiology, 2015
- EGFR T790M resistance mutation in non small-cell lung carcinomaClinica Chimica Acta, 2015
- Correlation Between PET/CT Parameters and KRAS Expression in Colorectal CancerClinical Nuclear Medicine, 2014
- NF-κB protein expression associates with 18F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolismLung Cancer, 2014
- Illuminating Radiogenomic Characteristics of Glioblastoma Multiforme through Integration of MR Imaging, Messenger RNA Expression, and DNA Copy Number VariationRadiology, 2014
- Technical and implementation issues in using next-generation sequencing of cancers in clinical practiceBritish Journal of Cancer, 2013
- Radiogenomic Analysis of Breast Cancer Using MRI: A Preliminary Study to Define the LandscapeAmerican Journal of Roentgenology, 2012
- Non–Small Cell Lung Cancer: Identifying Prognostic Imaging Biomarkers by Leveraging Public Gene Expression Microarray Data—Methods and Preliminary ResultsRadiology, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Resistance to an Irreversible Epidermal Growth Factor Receptor (EGFR) Inhibitor in EGFR-Mutant Lung Cancer Reveals Novel Treatment StrategiesCancer Research, 2007